Showing 4661-4670 of 4941 results for "".
- Corena Therapeutics New to Industryhttps://practicaldermatology.com/news/20130513-corena_therapeutics_new_to_industry/2459546/The emerging Swiss dermatological products company Corena Therapeutics provides safe alternatives to popular treatments. Coresatin, its latest brand of five steroid-free creams, is safely formulated for pediatric patients, according to the
- Thermage Total Tip Available to Dermatologists Nationwidehttps://practicaldermatology.com/news/20130510-thermage_total_tip_available_to_dermatologists_nationwide/2459548/Solta Medical, Inc. launched the Thermage Total Tip 3.0 for face, neck, and body treatments. Targeted, uniform, bulk heating allows dermatologists to treat patients effectively while maintaining patient comfort, according to the company. Thermage
- AcneFree Products with Micro-Benzoyl Peroxide Now Availablehttps://practicaldermatology.com/news/20130430-acnefree_products_with_micro-benzoyl_peroxide_now_available/2459553/Formulated with Advanced Micro-Benzoyl Peroxide, new AcneFree Clear Skin Products from Valeant Consumer Products are formulated to effectively target acne with less irritation. Three kits are available: The AcneFree 24 Hour Acne Clearing System (AcneFree
- HydraSolve Cleared for Autologous Fat Transferhttps://practicaldermatology.com/news/20130425-hydrasolve_cleared_for_autologous_fat_transfer/2459559/The new Hydrasolve liposuction device has recently been FDA-cleared for autologous fat transfer, a first-of-its-kind indication in the liposuction realm. The new clearance enables clinicians to harvest and re-inject fat from the initial HydraSolve liposuction procedure for rejuvenations or augmentat
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- BTL Aesthetics Introduces Exilis Elitehttps://practicaldermatology.com/news/20130415-btl_aesthetics_introduces_exilis_elite/2459563/BTL Aesthetics recently introduced the Exilis ELITE, its next stage device for reducing wrinkles and treating skin laxity of the face and body. Optimizing the dynamic monopolar radiofrequency (RF) technology of the original Exilis system, the new ELITE platformoptimizes the monopolar radiofrequency
- Promius Pharma Introduces Zenatane and “The Promius Promise”https://practicaldermatology.com/news/20130412-promius_pharma_introduces_zenatane_and_the_promius_promise/2459565/Promius Pharma, LLC announced the introduction of Zenatane (Isotretinoin) Capsules, a newly approved isotretinoin option for patients with severe, recalcitrant, nodular acne. Zenatane will be supported by The Promius Promise, a pharmacy serv
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- “Dermatologist from the Heart” Program Seeks Grant Proposalshttps://practicaldermatology.com/news/20130410-dermatologist_from_the_heart_program_seeks_grant_proposals/2459567/“Dermatologist from the Heart” is a new program from La Roche-Posay that aims to support initiatives designed to enhance the quality of life for patients. The initiative will award a grant to the most compassionate project spearheaded by dermatologists that seek to enhance patients' quality of life.
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest